



Strategy and Sustainability Division
MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE

DH CIRCULAR No. 248/2010

DH 3836/2010

3rd November 2010

Attention all Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Aprepitant capsules

Aprepitant capsules, 125 mg/80 mg have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for the introduction into the Government Formulary List. The Consultant Oncologist and/or Palliative Care can prescribe Aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults. Aprepitant is protocol-regulated and the protocol number is 269 (attached).

Aprepitant capsules, 125 mg/80 mg have been procured through GHPS and are now available for use as per protocol.

Thank you

For your attention, please

Dr Natasha Azzopardi Muscat

Director General

Aprepitant 80mg and 125mg capsules

Prescriber Criteria: Consultant Oncologist
Palliative Care Consultant

Clinical Indications:

Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults.

Conditions qualifying patient for drug:

Patients requiring prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy. Persistent emesis despite formulary anti-emetics.

Treatment evaluation/Clinical parameters:

Symptomatic control

Objective indicators of efficacy:

Symptomatic control

Frequency of review:

6 cycles